Stephen Horrigan

Stephen Horrigan

Company: Iterion Therapeutics

Job title: Chief Scientific Officer


Inhibition of the WNT/beta catenin Pathway in NSCLC 12:00 pm

Understand the WNT/beta catenin pathway’s importance as a target in NSCLC Explore the new therapeutics in development to inhibit this target Combination with EGFR inhibitors has potential to impact disease progressionRead more

day: Day Two

Panel Discussion: Exploring the Strategic Challenges of Moving Forward a Drug You Want to Combine with PD-1 in Chemo+PD-1 Progressors 12:30 pm

Understanding the different current comparators and benchmarks Exploring the differences in PD-1 naïve and PD-1 progressors Dissecting why sometimes beating chemo and PD-1 could be an unachievable bar Discussing whether with late-line in-effectivity, how you know it won’t work in early line? Considering the health authorities’ standards on the matterRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.